转移性肾细胞癌治疗中晚期肾透明细胞癌的预后——一项德国单中心真实世界经验
mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma - A German Single-center Real-world Experience.
作者信息
Schwab Maria, Hofmann Rainer, Heers Hendrik, Hegele Axel
机构信息
Department of Urology and Pediatric Urology, University Medical Center, Marburg, Germany
Department of Urology and Pediatric Urology, University Medical Center, Marburg, Germany.
出版信息
In Vivo. 2018 Nov-Dec;32(6):1617-1622. doi: 10.21873/invivo.11422.
BACKGROUND/AIM: Since the advent of targeted therapeutics, paradigms in metastatic renal cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data from randomized controlled trials can be transferred into real-world settings.
PATIENTS AND METHODS
All patients with mRCC treated from 2006-2015 at the Department of Urology (Marburg-Germany) were retrospectively analyzed. Collected data include: Patient demographics, tumor characteristics, efficacy, safety, and used therapy sequences.
RESULTS
In total, 197 patients with mRCC were identified. About one third of patients reached third-line therapy. Median overall survival in real-world amounted to 25.8 months with a five-year survival rate of 30% with significant differences between IMDC risk groups (p<0.01). Response rates were highest using tyrosine kinase inhibitor (TKI). Patients with response to therapy showed significantly improved survival (p<0.05). Side-effects in each therapy line were manageable in daily practice.
CONCLUSION
Our data suggest that targeted therapy in the treatment of mRCC is effective and safe in daily clinical practice and for real-world patients.
背景/目的：自靶向治疗出现以来，转移性肾细胞癌（mRCC）的治疗模式发生了变化。我们研究了随机对照试验的疗效和安全性数据是否可以应用于实际临床环境。
患者与方法
对2006年至2015年在德国马尔堡泌尿外科接受治疗的所有mRCC患者进行回顾性分析。收集的数据包括：患者人口统计学资料、肿瘤特征、疗效、安全性以及所采用的治疗方案。
结果
共确定了197例mRCC患者。约三分之一的患者接受了三线治疗。实际临床环境中的中位总生存期为25.8个月，五年生存率为30%，国际转移性肾细胞癌数据库（IMDC）风险组之间存在显著差异（p<0.01）。使用酪氨酸激酶抑制剂（TKI）时缓解率最高。对治疗有反应的患者生存期显著延长（p<0.05）。在日常临床实践中，各治疗线的副作用均可控制。
结论
我们的数据表明，在日常临床实践中，对于实际临床环境中的患者，mRCC的靶向治疗是有效且安全的。
Zotero 插件